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Abstract
Background: Graves’ disease (GD) is an autoimmune condition in which autoantibodies to the thyrotropin receptor
(TSHR) cause hyperthyroidism. About 50% of GD patients also have Graves’ orbitopathy (GO), an intractable disease
in which expansion of the orbital contents causes diplopia, proptosis and even blindness. Murine models of GD/GO,
developed in different centres, demonstrated significant variation in gut microbiota composition which correlated
with TSHR-induced disease heterogeneity. To investigate whether correlation indicates causation, we modified the
gut microbiota to determine whether it has a role in thyroid autoimmunity. Female BALB/c mice were treated with
either vancomycin, probiotic bacteria, human fecal material transfer (hFMT) from patients with severe GO or ddH2O
from birth to immunization with TSHR-A subunit or beta-galactosidase (βgal; age ~ 6 weeks). Incidence and severity
of GD (TSHR autoantibodies, thyroid histology, thyroxine level) and GO (orbital fat and muscle histology),
lymphocyte phenotype, cytokine profile and gut microbiota were analysed at sacrifice (~ 22 weeks).
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Results: In ddH2O-TSHR mice, 84% had pathological autoantibodies, 67% elevated thyroxine, 77% hyperplastic
thyroids and 70% orbital pathology. Firmicutes were increased, and Bacteroidetes reduced relative to ddH2O-βgal;
CCL5 was increased. The random forest algorithm at the genus level predicted vancomycin treatment with 100%
accuracy but 74% and 70% for hFMT and probiotic, respectively. Vancomycin significantly reduced gut microbiota
richness and diversity compared with all other groups; the incidence and severity of both GD and GO also
decreased; reduced orbital pathology correlated positively with Akkermansia spp. whilst IL-4 levels increased. Mice
receiving hFMT initially inherited their GO donors’ microbiota, and the severity of induced GD increased, as did the
orbital brown adipose tissue volume in TSHR mice. Furthermore, genus Bacteroides, which is reduced in GD
patients, was significantly increased by vancomycin but reduced in hFMT-treated mice. Probiotic treatment
significantly increased CD25+ Treg cells in orbital draining lymph nodes but exacerbated induced autoimmune
hyperthyroidism and GO.
Conclusions: These results strongly support a role for the gut microbiota in TSHR-induced disease. Whilst changes
to the gut microbiota have a profound effect on quantifiable GD endocrine and immune factors, the impact on GO
cellular changes is more nuanced. The findings have translational potential for novel, improved treatments.
Keywords: Graves’ disease, Graves’ orbitopathy, Murine model, Gut microbiota, Microbiome modulation,
Vancomycin, Probiotics, Human fecal microbiota transplant
Background
There is an interdependent relationship between the
host immune system and the gut microbiota. Differenti-
ation of naïve CD4+ T cells in the gut-associated lymph-
oid tissue is modulated by microbial metabolites [1].
Consequently, autoimmune disease, including type-1
diabetes (T1D) and multiple sclerosis (MS), is influenced
by the gut microbiota composition [2–7]. Perturbation
of the gut microbiota may improve or exacerbate auto-
immunity, for example, administration of antibiotic to
female systemic lupus erythematosus-prone mice attenu-
ates disease [8], but human fecal material transfer
(hFMT) from MS patients increased the frequency of
murine autoimmune encephalomyelitis (EAE) [9]. In
contrast, administration of probiotics to EAE mice re-
sulted in a milder disease phenotype [10] and reduced
inflammation in a model of autoimmune thyroid disease
(ATD) [11].
Little is known regarding the role of the microbiome
in Graves’ disease (GD), which is characterized by
thyroid-stimulating antibodies (TSAbs) binding to the
thyrotropin (TSH) receptor (TSHR) resulting in thyroid
hyperplasia and hyperthyroidism [12–14]. The TSHR is
expressed in orbital fibroblasts and up to 50% of GD pa-
tients also have Graves’ orbitopathy (GO), in which or-
bital tissue remodeling causes eye redness, swelling,
diplopia, proptosis and vision impairment [15–17]. Gen-
etic background and environmental factors, e.g. stress,
smoking and pregnancy, combine to increase predispos-
ition to GD and GO [18–22]. Bacterial infections have
also been implicated [23], as have immune responses to
food and other antigens [24].
We recently described a relationship between the gut
microbiota and thyroid autoimmunity [25] in a robust
GO mouse model in which female BALB/c (H-2d) mice
were immunized with the TSHR-A subunit (TSHR
extracellular region) via plasmid electroporation [26, 27].
Differences in the induced disease were noted in the
same mouse strain (BALB/c) but in two different labora-
tories, e.g. hyperthyroidism only in one centre accompan-
ied by significant differences in alpha-diversity, beta-
diversity and taxonomic profiles between the two centres.
We also observed a shift in beta-diversity of bacterial com-
munities in TSHR-immunized mice compared to controls
and a positive correlation between Firmicutes and orbital
adipogenesis [25, 28]. When comparing mice of differing
strains (BALB/c and C57BL/6J), but in the same housing,
we observed variations in orbital pathology, TSAbs, thy-
roxine levels and inflammation, accompanied by differ-
ences in microbiome composition. Bacterial genera were
also correlated with disease features, e.g. Clostridium-IV
and Anaerotruncus spp. positively correlated with TSAb
levels in BALB/c mice whereas Limibacter spp. correlated
negatively with TSAbs in C57BL/6J mice [25, 28].
However, correlation does not imply causation, and to
test the microbiota contribution to the GO model from
early life, we modulated its composition and assessed in-
duced disease phenotype.
Materials and methods
Mouse model and study outline
Female BALB/c mice used in this study were bred at the
Central Animal Laboratory, University Hospital Essen,
University of Duisburg-Essen, Essen, in order to adminis-
ter the treatments from an early stage of life. Breeding
pairs were purchased from Harlan, now Envigo, Rossdorf,
Germany. In total, 95 mice were included in the study.
Three of the 95 mice died for unknown reasons. The
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mouse cohort was divided into four groups receiving ei-
ther (i) the antibiotic vancomycin, (ii) the probiotic con-
sortium Lab4, (iii) freeze-dried human fecal material from
severely diseased GO patients and (iv) deionized water
(ddH2O) as control. The antibiotic vancomycin was pro-
vided in autoclaved drinking water at a dose of 0.2 g/l to
both dams first and pups later from their first day of life
for the entire course of the experiment. The probiotic
Lab4 (Cultech Ltd., Port Talbot, Wales, UK) is a consor-
tium comprising two strains of Lactobacillus acidophilus
CUL60 (NCIMB 30157) and CUL21 (NCIMB 30156), Bifi-
dobacterium lactis CUL34 (NCIMB 30172) and Bifidobac-
terium bifidum CUL20 (NCIMB 30153). It was provided
as powder in a capsule, and loose powder was adminis-
tered at a total of 1 × 1010 CFU in 50 μl autoclaved water
per gavage. The hFMT powder was dissolved in auto-
claved water and provided at a final concentration of 1 ×
1010 CFU in 50 μl autoclaved water per gavage. Adminis-
tration of the probiotic Lab4, the hFMT powder and
ddH2O as control was performed through gavage on pups
a total of four times from the first day after birth, at wean-
ing, and before and in the mid of the immunization pro-
cedure, as described in Fig. 1a.
At an age of 6–7 weeks and after having received three
gavages or vancomycin continuously, mice from each
group were assigned to two subgroups for receiving
immunization with either the human thyrotropin recep-
tor (hTSHR)-A subunit (hTSHR) eukaryotic expression
plasmid pTriEx1.1Neo-hTSHR (hTSHR289) or the con-
trol plasmid pTriEx1.1Neo-β-gal, as a plasmid-control
group (βgal) via intramuscular injection with 50 μl (1
mg/ml) into each M. biceps femoris and electroporation
four times at three week intervals [26, 29, 30]. All plas-
mids were purified from E. coli extracts and stored ali-
quoted at − 80 °C. As an electroporation system, a BTX
Gemini X2 with 7-mm calliper electrodes at 120 V/cm
was used with current application in two series of six
20-msec2 wave pulses at 1 Hz. Anaesthesia of each
mouse was conducted with an isoflurane vaporizer
throughout the immunization procedure. Mice were
kept in individually ventilated cages under specific
pathogen-free (SPF) conditions throughout the study.
Animals were fed water and commercial diet ad libitum.
Animals were sacrificed 6 weeks after the last
immunization or at an age of 22 weeks, respectively.
Mouse weights were noted at the endpoint of the study
(balance 440-45N (Kern und Sohn GmbH, Balingen,
Germany).
Recruitment of patients with severe Graves’ orbitopathy
for human fecal microbiota transplant (hFMT) production
Six Graves’ orbitopathy patients with sight-threatening
disease were recruited at the Ophthalmic Clinic of the
University Hospital of Duisburg-Essen (Germany). Eye
disease activity and severity were assessed based on the
EUGOGO guidelines [31]. Five of the six patients
stopped steroid intake at least 2 months prior to sample
collection, whereas one patient took steroids in the
month of sampling. None of the six patients received
immunosuppressive drugs before sampling, and receipt
of antibiotics in the previous 3 months excluded poten-
tial donors. All six patients were treated with steroid
bolus and selenium before orbital decompression sur-
gery (performed between 2014 and 2015). One patient
(GO 4) had the decompression of both eyes, and two pa-
tients (GO 4 and GO 5) continued steroid treatment
after surgery. Assessment of thyroid blood parameters
(TSH and total serum T4) and thyroid-stimulating anti-
bodies (TRAB) was performed according to bioassays
used in the central laboratory at University Hospital
Essen, Germany. A complete description of the patient
characteristics used for hFMT production is described in
Table S1. Donors were instructed in person before the
procedure regarding stool collection and delivery. Subse-
quent fecal samples were collected at the time of enrol-
ment, stored at − 80 °C and shipped frozen to Cultech
Ltd. (Port Talbot, UK) for the production of the fecal
microbiota transplant (hFMT). Each single fecal sample
underwent traditional microbial cultures and DNA ex-
traction for 16S rRNA gene sequencing.
Production of freeze-dried fecal bacteria for human fecal
microbiota transplant (hFMT)
To assess numbers of living bacteria in feces, 1 gram of
feces per patient was diluted in 9 ml pre-reduced max-
imum recovery diluent (CM0733, Oxoid, Basingstoke,
UK) with 20% v/v glycerol. The solution was mixed by
vortexing for 5 s. Then, 10-fold serial dilutions were pre-
pared, and 100 μl of each dilution was plated onto differ-
ent culture media under aerobic or anaerobic conditions
(Anaerobic Workstation, AW400SG, Elektrotek, Keigh-
ley, West Yorkshire, UK). In order to isolate different
bacteria, the following media, culture conditions and di-
lutions were used as described in [25], see additional
methods. For hFMT production, blended fecal samples
were run through a sequential culture method. There-
fore, 0.1 g of pooled and blended feces was added to 50
mL pre-reduced maximum recovery diluent (MRD)
broth and incubated overnight at 37 °C under aerobic
and anaerobic conditions. The mixture was further inoc-
ulated into 500 mL pre-reduced MRD, followed by an
overnight incubation at 37 °C under aerobic and anaer-
obic conditions. As a control, pooled fecal samples from
each inoculum were plated on the non-selective agars
horse blood agar and anaerobic blood agar (both pur-
chased from Thermo Fisher Scientific Oxoid Ltd,
Basingstoke, UK) and incubated overnight at 37 °C under
aerobic or anaerobic conditions in order to count viable






Fig. 1 Early-life manipulation treatments modified the lower gastrointestinal microbiota with long-term effects in TSHR-immunized mice. a
Rationale of early-life manipulation treatments combined with the hTSHR-immunization procedure, see STAR methods for complete description.
b Alpha-diversity indices amongst treatments. Wilcoxon-Mann test BH corrected: ***P < 0.001; **P = 0.019; *P = 0.045. c Significantly differentially
abundant genera between immunizations in each treatment. Welch’s t test, BH corrected: ***P < 0.001; **P = 0.011; *P = 0.04. d Random forest
confusion matrix of the classification for treatments (all immunizations together). Diagonal boxes represent the number of samples correctly
predicted. The RF model accounted for 73.08% accuracy (n mice/group endpoint: control = 20, hFMT = 19, Lab4 = 20, vancomycin = 19). e Top-
10 important variables contributing to treatment classification according to the Mean Decrease Gini, related to e. f RandomForest confusion
matrix of the classification for immunizations. The RF model accounted for 70.51% accuracy (n mice/immunization endpoint: TSHR = 43, βgal =
35). g Top-10 important variables contributing to immunization classification according to the Mean Decrease Gini, related to g
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cells. After a centrifugation step at 3000×g for 30 min,
the resulting supernatant was discarded and the pellet
was weighed and poured into sterile petri dishes, where
they were supplemented with 10% w/v skimmed milk
powder as a cryoprotectant agent, and placed at − 80 °C
until completely frozen. The freeze-drying process was
performed in a freeze-dryer machine (Super Modulyo
freeze dryer, Edwards, Clevedon, North Somerset, UK).
The frozen sample was moved into the freeze-drier with
a shelf temperature of − 30 °C; afterwards, the vacuum
was started, the temperature was slowly decreased to −
15 °C and the samples were kept under these conditions
overnight. Finally, the temperature was raised to 0 for 2
h and subsequently raised to 20 °C for another 2 h. To
count viable bacterial cells in the hFMT powder for
quality purposes, 50 μl from a stock of 0.5 g hFMT pow-
der was diluted in 4.5 mL MRD, streaked out on non-
selective agars (horse blood agar for total aerobic bac-
teria and anaerobic blood agar for total anaerobe bac-
teria) as well as on agars selective for lactobacilli (Man,
Rogosa and Sharpe broth (MRS) agar) and for bifidobac-
teria (MRSx agar). Agars were incubated overnight at
37 °C or for 48 h in the case of MRSx agar; conditions
were aerobic (horse blood agar and anaerobic blood
agar) or anaerobic conditions (MRS and MRSx), respect-
ively. The resulting powder was aliquoted into small
vials to 0.125 g final content and shipped to the Univer-
sity Hospital Essen.
Mouse fecal sample collection
Individual fecal pellets from mice were collected after
three treatment gavages but before any immunizations
with hTSHR or βgal (baseline), and after four gavages
but before the third immunization (mid-timepoint). The
contents of colon or entire intestines were collected for
metataxonomic analysis after the sacrifice of the mice (6
weeks after the last immunization and nearly 9 weeks
after the last gavage).
DNA extraction and sequencing
DNA was extracted using the QiAmp Fast DNA Stool
Mini kit (Qiagen Ltd, West Sussex, UK). Collected sam-
ples were individually placed in 2-mL tubes prefilled
with 0.1 mm silica and zirconia bead mix (Benchmark
Scientific, Edison, USA), dissolved in 1 mL InhibitEX
buffer (Qiagen Ltd, West Sussex, UK) and vortexed until
homogenized. A bead-beating step (Beadbug microcen-
trifuge homogenizer, Benchmark Scientific, USA) was
applied for 3 x 60 s at 5 m/s with 5-min rest in between.
Total genomic DNA was eluted in sterile microcentri-
fuge tubes and quantified by Qubit Fluorimetric Quanti-
tation (ThermoFisher Scientific Ltd, UK) as per
manufacturer’s instructions. Metataxonomic sequencing
(16S rRNA gene sequencing) was performed at Research
& Testing RTL Genomics (Lubbock, TX, USA), using
primers detecting the V1-V2 regions of the 16S rRNA
gene plus bifidobacteria regions to generate 10,000
paired-ends reads on a Illumina MiSeq (Illumina, San
Diego, USA.
Processing of sequencing reads
A first quality check on raw demultiplexed paired-end
sequences (R1 and R2) was done using FastQC. All of
the below steps were performed with the quantitative in-
sights into microbial ecology (QIIME) 1.9 open-source
bioinformatics pipeline for microbiome analysis [32].
Joining of paired-end sequences was done using the
function “multiple_join_paired_end.py”, with the Seq-
Prep method (https://github.com/jstjohn/SeqPrep).
Quality filtering of the reads was performed according to
the following parameters: (i) maximum of three consecu-
tive low-quality base calls (Phred < 19) allowed and (ii)
fraction of consecutive high-quality base calls (Phred >
19) in a read over total read length > = 0.75; iii) no “N”-
labeled bases (missing/uncalled) allowed. A total of 13,
782,107 reads were obtained before quality filtering in-
cluding also the small intestines samples. The reads per
group were as the following: ddH2O 2,593,620; hFMT 2,
972,296; Lab4 2,102,509; vancomycin 5,280,854 and GO
patients 483,510 (n = 6, i.e. reads were sequenced in a
separate run with the same primers and were processed
together with mouse reads processing using QIIME and
unknown 349,318). Reads were reduced to a total of 12,
884,785 after quality filtering (reads per group: ddH2O 2,
418,786; hFMT 2,757,051; Lab4 1,945,969; vancomycin
5,003,546; GO patients 428,852 and unknown 330,581).
Passing-filter reads were aligned against the SILVA 123
reference database using the “pick_closed_reference_
otus.py” approach for taxonomic assignment with a 97%
cluster identity [33]. Operational taxonomic unit (OTUs)
with total counts lower than 15 in fewer than 2 samples
were filtered out. To correct potential biases in library
size due to sampling procedures or sequencing depth,
OTUs were normalized in each library through the cu-
mulative sum scaling (CSS) [34] implemented in the
“normalized_table.py” function. Filtered and normalized
OTUs were collapsed into each phylogenetic level (from
phylum to genus) using the function “taxa_summary.py”.
Serological analysis of mouse blood
Anti-TSHR antibodies (TRAbs) and TSH-stimulating
antibodies (TSAbs) and total T4 were evaluated in
mouse serum [27, 35]. Therefore, TRAbs were measured
in commercial TRAK kits using 25 μl serum plus 75 μl
human control serum as TSH binding inhibitory immu-
noglobulins activity in competition with labeled bTSH to
the human TSHR (ThermoFisher, BRAHMS, Germany).
TSAbs were measured in 3 μl serum plus 147 μl buffer
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in a bioassay using stably transfected mouse TSHR-
Chinese hamster ovary cells (CHO) cells kindly provided
by Sandra McLachlan [29, 30]. TSHR-CHO cells were
incubated with test sera diluted 1:20 in Ham’s F12 sup-
plemented with HEPES 10mM (pH 7.4) and isobutyl-
methylxanthine 1 mM in 96-well plates for 80 min at
37 °C. Intracellular cAMP was extracted with ethanol
after aspirating the medium, evaporated to dryness and
resuspended in Dulbecco’s PBS. The concentration of
TSAbs is directly correlated to the cAMP production of
the cells. cAMP concentration in 100 μl of the mouse
TSHR-CHO cells supernatants was measured by ELISA
(Enzo, Farmingdale, NY, USA). Total T4 concentrations
were measured in 25 μl serum by ELISA (DRG, Spring-
field, NJ, USA).
Histopathology of thyroid glands and orbits
The thyroids were formalin fixed and paraffin embed-
ded, and sections (1 μm) H&E stained. Thyroidal morph-
ology was blindly evaluated by two different observers
and indexed as hyperactive, heterogeneous or normal in
comparison to the thyroid morphology of the respective
βgal mice. Hyperplastic glands (indicating hyperthyroid-
ism) were characterized by increased total size, cuboid
cylindrical follicular cells with minimal colloid and thick
follicular epithelium. Numbers of mice displaying nor-
mal, heterogeneous or hyperactive thyroid morphology
are given in %. The orbits were formalin fixed and paraf-
fin embedded. Orbital slices (1 μm) at the anterior, mid-
dle and posterior area of the mouse orbits were H&E
stained and examined. Quantification of adipose tissues
and muscle atrophy in extraocular inferior rectus and
medial rectus muscle was performed with ImageJ. The
area of adipose tissue was normalized to the optic nerve
area. Atrophic cells were identified by diameter (<
50 μm) and round shape of muscle fibers [27, 35]. Im-
ages were generated using an Olympus BX51
microscope.
Analysis of lymph node T cell subsets by flow cytometry
Draining lymph nodes of mouse orbits were harvested
and teased apart into a single-cell suspension by mash-
ing tissue between two frosted microscope slides. Col-
lected cells were filtered using a 100-μm cell strainer to
eliminate clumps and before centrifuging 5min 400×g at
4 °C. Cell pellet was then resuspended in 1 ml of PBS
with 2% FBS to count and evaluate cell viability. Appro-
priate volumes of each sample equal to 2 × 106 cells
were transferred to new tubes for staining. Antibody mix
of CD4 FITC, CD8PE and CD25 APC (all from BioLe-
gend) was added to each sample and added up to 100 μl
using PBS with 2% FBS. Cells were incubated for at least
30 min at 2–8 °C before washing and spinning down at
400×g for 5 min. Cells were resuspended in 300 μL of
PBS with 2% FBS and subjected to read by flow
cytometry.
Measurement of circulating cytokines in mouse serum
CCL5, IL-4, CCL20, IFN-γ, IL-2, IL-6, IL-10, IL-17/IL-
17A and TNF-alpha in murine sera were measured by
polystyrene bead-based Luminex technology (R&D
Systems, Minneapolis, USA) according to the manufac-
turer’s instructions, and the assay was run on a Luminex
200 instrument (Luminex Corporation, Austin, TX,
USA).
Statistical analysis
Results are presented as mean ± standard error of the
mean. Multiplicity adjusted P values are marked as fol-
lows: *≤ 0.05; **≤ 0.01; ***≤ 0.001; ****≤ 0.0001. Changes
between mouse groups with P values > 0.05 are regarded
as not statistically significant and are not marked in the
graphs. Additionally, the upper 99% confidence interval
(CI) of the control βgal group was defined as the thresh-
old for positivity of individual mice and is indicated by a
dotted line when appropriate. In order to compare the
total outcome between the groups, we combined the key
parameters of either autoimmune hyperthyroidism
(TSAbs and T4) or orbitopathy (brown adipose tissue
(BAT) and atrophic fibers) by using the Z-score method.
The standard score (Z-score) was used to compare results
from different mouse groups normalized to the mean
value of the total mouse population (reference popula-
tion). The Z-score values (arbitrary units) represent the
values of standard deviation from the mean value of the
reference population. We also categorized severity of in-
duced disease: Subclinical disease (Z-score < 0): These
mice did not develop significant autoimmune hyperthy-
roidism and/or GO. Clinical disease (Z-score > 0): These
mice displayed signs of overt disease during the experi-
ment. Clinical disease is classified in accordance with Z-
score values as mild (Z-score 0 > 1) or moderate-to-severe
(Z-score > 1). The number of mice is given in %. Bacterial
counts data were Box-Cox transformed before statistical
analysis [36]. Otherwise stated, statistical analyses for 16S
rRNA gene sequencing data were performed in R v3.4.1.
Alpha- and beta-diversity indices were obtained from the
filtered OTU-table in QIIME. Kruskal-Wallis and pairwise
Wilcox-test with Benjamini-Hochberg (BH) adjustment
for multiple corrections were used to test the association
between alpha-diversity indices and variables (e.g. immu-
nizations, treatments or microbiota sources). Dissimilar-
ities amongst groups (treatments/immunizations) or
pairwise dissimilarities along variables were evaluated
non-parametrically using the permutational analysis of
variance approach (PERMANOVA) with 999 permuta-
tions [37], implemented in the R Vegan package. When
necessary, a stratification of the permutations was applied
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to correct for the different microbiota sources sampled
(e.g. entire and colon samples). Differential abundant tax-
onomies were identified using a linear regression model.
Random forest (RF) was employed to classify samples ei-
ther amongst treatments (ddH2O, hFMT, Lab4 or vanco-
mycin) or between immunizations (βgal or TSHR) based
on their microbiota composition and to identify genera
driving the classification (variable importance). Correla-
tions between disease features and bacterial biomarkers
were assessed using the Pearson’s correlation coefficient
(r), using the Corrplot R package. The extent of the hFMT
between donors and recipients—or engraftment [38]—was
calculated using the SourceTracker R package [39]. A de-
tailed description of the methods performed is available in
Additional Methods.
Results
The mouse cohort comprised four groups receiving differ-
ent treatments: (i) vancomycin antibiotic; (ii) Lab4 pro-
biotic consortium (2 strains of Lactobacillus acidophillus,
1 strain Bifidobacterium animalis, 1 strain Bifidobacter-
ium bifidum); (iii) freeze-dried human fecal material
(hFMT) from 6 severe GO patients; (iv) ddH2O as con-
trol, as described in Fig. 1a. Pups were gavaged with either
Lab4 or hFMT or ddH2O 1 day after birth, at weaning,
and before and in the middle of immunizations whereas
dams and their pups (from birth) received vancomycin in
their drinking water throughout the experiment.
Early-life manipulation treatments conferred enduring
changes of the TSHR-immune lower gastrointestinal
microbiota
At the end of the experimental procedure (Fig. 1a), 9
weeks after the last gavaged treatment, the microbiota
was sampled and analysed via 16S rRNA gene sequen-
cing, from the large intestines in vancomycin, hFMT
and ddH2O groups. The gut microbiota was obtained
from the entire intestine of Lab4-treated and a related
group of ddH2O-receiving mice. A total of 3623 OTUs
with more than 15 counts in at least two samples were
retrieved from quality-filtered reads and used in further
analyses. There were no significant differences in alpha-
and beta-diversity indices between the entire and the
large intestines (Figure S1A–B); therefore, data from the
two anatomical sources were combined and referred to
as lower gastrointestinal tract (LGI) microbiota.
Vancomycin-treated LGI microbiota had drastically re-
duced richness and diversity compared to ddH2O, hFMT
and Lab4 mice, in both TSHR and βgal-immunized mice
(Fig. 1b and S1C, respectively). Firmicutes-prevalent gen-
era such as Faecalibacterium, Eubacterium, Ruminiclos-
tridium and Ruminococcaceae spp. were depleted from
vancomycin LGI microbiota in both TSHR (Figure S2)
and βgal mice (Figure S3), whilst Bacteroides spp. showed
the highest counts compared to ddH2O-, Lab4 -and
hFMT-TSHR-immunized mice. Potential vancomycin-
resistant bacteria were present, including Proteobacteria
genera Enterobacter, Salmonella, Pseudomonas spp. and
E. coli. Interestingly, Verrucomicrobia genus Akkermansia
increased in TSHR compared to βgal vancomycin-treated
mice (P = 0.011, Fig. 1c). The unique vancomycin micro-
biota composition facilitated 100% per-class prediction ac-
curacy (19/19) using the random forest algorithm with 10,
000 decision trees, to predict early-life treatments in end-
point samples’ genus-level gut microbiota (Fig. 1d–g).
TSHR-Lab4 mice showed a lower equitability index
compared to TSHR-ddH2O mice (P = 0.045, Fig. 1b).
Differentially abundant genera were observed after Lab4
administration, with twelve genera showing increased or
decreased relative abundance when compared with
TSHR-ddH2O mice (data not shown). In contrast to the
vancomycin treated mice, Akkermansia spp. decreased in
TSHR-Lab4 compared to βgal-Lab4 (P = 0.040, Fig. 1c).
Bacteria in the hFMT powder were viable (Figure
S4A). TSHR-hFMT had reduced Shannon diversity com-
pared to TSHR-ddH2O mice (P = 0.019, Fig. 1b), whilst
no significant differences occurred in βgal mice (Figure
S1A). At genus level, TSHR-hFMT mice showed signifi-
cantly lower Bacteroides spp. counts compared to
ddH2O (P = 0.003, Figure S2). Following pairwise com-
parison, sixteen genera were differentially abundant
compared to the TSHR-ddH2O group (data not shown).
Bacteroides spp. were significantly reduced in hFMT-
TSHR compared to hFMT-βgal mice (P < 0.001, Fig. 1c),
as previously reported [25] and between GO patients
and healthy controls (Figure S4B–D).
Differences in the Lab4 and hFMT LGI microbiota
composition were sufficient for predicting treatment
with per-class accuracies of 70% (14/20) and 74% (14/
19), respectively. In contrast, the ddH2O group had a
per-class accuracy of 50% (10/20, Fig. 1d, e). In predict-
ing the immunizations, including all treatments, the βgal
group showed a 63% per-class accuracy (22/35 samples),
whilst 77% per-class accuracy for the TSHR (33/43, Fig.
1f, g). Similar outcomes were retained when repeating
the model without the vancomycin-treated group (Figure
S1D–G).
Combined effect of treatments, immunizations and time
on the fecal microbiota composition of GO mouse model
We assessed the impact of various treatments over time
by analysing the fecal microbiota after gavage but prior
to any immunization (baseline) and following 3 gavages
but before the third immunization (midpoint) (Fig. 1a).
At baseline, vancomycin treatment already produced
drastic effects, comparable to those reported at the end
of the experiment (Figure S5A). Compared to ddH2O-
controls, Lab4 increased both Chao1 (Figure S5A) and





Fig. 2 (See legend on next page.)
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observed OTUs indices, whilst hFMT reduced bacterial
diversity (Shannon) and evenness, but did not reach sig-
nificance. Lab4- and hFMT-treated mice displayed dif-
ferences in fecal microbiota composition compared to
ddH2O- and vancomycin-treated mice (i.e. reduced
counts of Bacteroides spp.), but the two groups differed
very little at baseline (Figure S5B). A significant differ-
ence in the Firmicutes to Bacteroidetes ratio was ob-
served between TSHR and βgal immunizations in the
hFMT-receiving mice (P = 0.0006, Fig. 2b). Similarity be-
tween hFMT-receiving mice and the GO human donors
(Fig. 2c) was calculated with the SourceTracker algo-
rithm [39] using the family-level microbiota compos-
ition. At baseline, 4 out of 15 hFMT-receiving mice fecal
samples (test) showed more than 40% similarity (min
46%, max 72%) with the GO donors’ source, whilst none
out of 16 ddH2O-receiving mice (control) shared any
similarity with the GO donors samples (Fisher’s exact
test with Yates’ continuity correction, P < 0.001; Fig. 2d).
At midpoint, diversity and evenness (but not richness)
of the vancomycin-treated gut microbiota further re-
duced compared to baseline. Conversely, richness indi-
ces significantly increased between baseline and
midpoint in TSHR-hFMT mice (P = 0.023 observed
OTUs and P = 0.019 Chao1, respectively), as in the
ddH2O group (P = 0.014 observed OTUs and P = 0.0038
Chao1; Figure S5C). Bray-Curtis-based non-metric di-
mensional scaling (NMDS) separation between hFMT
and Lab4 mice (considering the two immunizations to-
gether) was significant (Fig. 2a).
No significant differences in beta-diversity were ob-
served between TSHR and βgal immunizations at base-
line, except in the hFMT-treated mice (P = 0.008).
which lasted at the midpoint (P = 0.016, Fig. 2a). Cen-
troids (sampling distribution of the mean) of each
immunization were close to each other, replicating our
previous findings at the equivalent T2 timepoint
(Masetti et al., 2018). Bacteroides spp. significantly in-
creased with time in Lab4 mice, in both immunizations
(data not shown). At midpoint, none of the hFMT-
receiving mice (0/24) showed any similarity with the hu-
man donors (P < 0.001) whilst half of the ddH2O mice
(10/20) showed > 10% similarity of the gut microbiota
with GO donors (Fig. 2d). At the end of the experiment,
the same similarity to human donors was observed in
both murine controls (26%) and hFMT-receiving colon
samples (26%).
Influence of gut microbiota modifications on TSHR
directed autoimmunity
Antibodies to the human TSHR were measured by
Thyrotropin binding inhibiting immunoglobulins (TBII;
TRAb) and were significantly detected in all TSHR-
immunized mice, but not in βgal-ddH2O mice (P ≤
0.0001), indicating successful immunization (Fig. 3a).
Thyroid-stimulating antibodies (TSAb) were measured
using a mouse TSHR overexpressing CHO cell-based
bioassay. ddH2O-, Lab4- or hFMT-treated TSHR-
immunized mice showed a statistically significant induc-
tion of TSAb compared to respective βgal mice (P ≤
0.0001) but not in the vancomycin-treated group (Fig.
3b). We also quantified percentages of mice developing
significant TSAB based on the upper 99% CI of the re-
spective βgal mouse group as the positive threshold
(Table S2). Eighty-four percent of TSHR-ddH2O mice
developed significant TSAB; treatment with Lab4 or
hFMT increased positivity to 90% and 100%, respect-
ively, but vancomycin treatment reduced TSAB to 64.3%
of mice (Table S2).
Disease features were correlated with the bacterial bio-
markers identified by the two random forest models by
Pearson’s correlation coefficient. In TSHR-ddH2O, six
genera including Parabacteroides counts correlated posi-
tively with TRAbs. Positive correlations were also ob-
served between TRAB and counts of unidentified/
uncultured Firmicutes in TSHR-vancomycin mice and
with Parabacteroides in TSHR-hFMT. Negative correla-
tions were seen in TSHR-hFMT mice between TRAB
and Lactobacillus and in TSHR-Lab4 between TSAB
and uncultured Firmicutes, Lachnoclostridium and un-
cultured Bacteroidetes (Figure S6) and a strong negative
correlation with the genus Lactobacillus.
Effect of microbiome modification on thyroid function
Total T4 values tended to increase in TSHR-immunized
groups, with Lab4-treated showing significantly higher
T4 compared to the corresponding βgal (P ≤ 0.05) (Fig.
3c). Based on the 99% CI of the relevant βgal-
(See figure on previous page.)
Fig. 2 Effect of treatments, immunizations and time on the GO model gut microbiota. a Differences between immunizations at each timepoint
and per treatment. PERMANOVA with 999 permutations, ***P = 0.008 and **P = 0.016 (n mice/treatment/immunization at baseline: control TSHR
= 10, βgal = 6; hFMT-TSHR = 9, βgal = 6; Lab4 TSHR = 9, βgal = 5; vancomycin TSHR = 12, βgal = 8) (n mice/treatment/immunization at mid-
timepoint: control TSHR = 11, βgal = 9; hFMT-TSHR = 5, βgal = 9; Lab4 TSHR = 11, βgal = 11; vancomycin TSHR = 14, βgal = 4). b Firmicutes to
Bacteroidetes ratio comparing immunizations in each timepoint and within each treatment group. Welch’s t test with BH correction: ***P =
0.0006. c Rationale of the SourceTracker analysis (see STAR methods). Human GO donors (n = 6), murine controls (n control/timepoint: baseline =
16, mid = 20, final =20) and hFMT-receiving mice (n hFMT/timepoint: baseline = 15, mid = 24, final = 19). d Pie charts: engraftment expressed as
average % probability using the control and the test analysis in each timepoint. Unknown: observations not assigned to a specific source at the
significant threshold (a = 0.001)
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immunized mice, 66.7% of TSHR-ddH2O mice had ele-
vated T4 levels which increased to 73% and 75% in
Lab4- or hFMT-treated respectively but reduced to 36%
in vancomycin mice (Table S2). Histological examination
of the thyroid revealed variable hyperplastic morphology
(thickened epithelium, reduced colloid) indicating gland
hyperactivity in TSHR-immunized mice but not in the
βgal groups (Fig. 3d, e). Some thyroids had heteroge-
neous morphology with normal regions and areas of hy-
perplastic follicles (Fig. 3e, arrows). Hyperplastic/
Fig. 3 Mouse TSHR antibody evaluation and impact of gut microbiome modification on thyroid function and morphology. a Total TSHR
antibodies (TRAbs) were measured by TSH binding inhibitory immunoglobulin activity to the human TSHR given as % inhibition of bTSH. b
Thyroid-stimulating autoantibodies (TSAbs). Stimulating activity is given in cAMP (pmol/mL). Data are presented as mean ± standard error of the
mean. Multiplicity adjusted P values are marked as follows ****P < 0.0001, ***P < 0.001, *P < 0.05 (two-way ANOVA). c Total T4 values (μg/dl) in
βgal- and TSHR-immunized mice from each treatment group *P < 0.05. d H&E of thyroid slices for thyroid morphology evaluation (in normal,
heterogeneous (hetero) or hyperthyroid (hyper)). e Representative thyroid images at × 20 magnification. Heterogeneous thyroids contained
normal and hyperthyroid regions (indicated by arrows). f Weights of animals at the endpoint of the experiment. Data are presented as mean ±
standard error of the mean. Multiplicity adjusted P value is marked as **P < 0.01 (two-way ANOVA)
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heterogeneous morphology was found in 46% and 31%
respectively, of TSHR-ddH2O mice (Fig. 3d). Lab4 and
hFMT increased hyperplastic thyroid to 60% and 83%,
respectively (Fig. 3d). The hFMT morphology paralleled
their increased TSAb and elevated T4 levels when com-
pared with other groups (Table S2). In contrast, vanco-
mycin reduced hyperplastic thyroids to 38% with 39%
having heterogeneous morphology, suggesting milder
hyperactivity of the gland compared to other mice (Fig.
3e, Table S2). In addition, weights of hFMT-treated
TSHR-immunized mice were significantly increased
compared to βgal-immunized mice (Fig. 3f).
TSHR-ddH2O mice showed positive correlations be-
tween T4 and the same three Firmicutes genera correlat-
ing with TSAB. Positive and negative correlations were
observed between T4 and Lachnoclostridium and the
genus Ruminiclostridium in vancomycin- and Lab4-
treated, respectively (Figure S6).
Microbiome modification modulates Graves’ orbitopathy
Individual TSH-immunized mice developed eye signs,
e.g. proptosis and inflammation, indicating orbitopathy
to different degrees which were difficult to quantify ob-
jectively (Suppl. Figure S7A). To determine the impact
of gut microbiome modification on orbitopathy, histo-
logical sections of mice orbits were analysed. We have
previously shown that the mouse orbit contains TSHR-
positive brown adipose tissue (BAT) which is enlarged
in the GO model [40–42]. Orbital BAT is character-
ized by small fat lobules and can be distinguished
from orbital white adipose tissue (Fig. 4a, Suppl. Fig-
ure S7B). In agreement with our earlier studies, BAT
area increased in the orbital tissue of TSHR-ddH2O
mice (69% positive mice based on 99% CI) compared
to βgal-ddH2O mice (P ≤ 0.001; Fig. 4b). Enlargement
of BAT was enhanced in TSHR-immunized mice
treated with Lab4 (P ≤ 0.01; 81.8% positive mice) or
hFMT (100% positive mice). In contrast, vancomycin-
treated TSHR-immunized mice had a much lower
portion of BAT positive mice (53.8%) compared to
the other TSHR-immunized mouse groups (Table S2).
Previously, we described muscle atrophy (smaller
muscle fibers, Fig. 4c arrows) as another feature of
orbitopathy in TSHR-immunized mice [27]. Signifi-
cant muscle fiber atrophy was detected in TSHR-
ddH2O mice compared to βgal-ddH2O group (P ≤
0.05) and not in the other three groups (Fig. 4d).
Based on 99% CI, 70% of TSHR-ddH2O mice devel-
oped significant muscle atrophy whilst 63.6% of
Lab4-, 44.4% of hFMT- or 66.7% of vancomycin-
treated TSHR-immunized mice had some muscle at-
rophy (Table S2). However, lymphocytic infiltrations
were not detected in the orbital tissues (Suppl. Figure
S7C, D).
Fig. 4 Gut microbiome modification modulates orbital tissue abnormalities in GO mouse model. The orbits of mice were fixed, paraffin
embedded, and consecutive slices of the middle orbital area were stained with H&E and evaluated for a brown adipose tissue (BAT);
representative images are shown, magnification × 10. b BAT as the percentage of the total fat area. c Atrophic fibers in extra orbital muscles;
representative images are shown, magnification × 20, arrows indicate areas with atrophic fibers. d atrophic fibers/total muscle fiber area (a.u.).
Data are presented as mean ± standard error of the mean. Multiplicity adjusted P values are marked as ***P < 0.001, **P < 0.01, *P < 0.05
(two-way ANOVA)
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In the vancomycin-treated TSHR-immunized group,
a strong negative correlation was observed between
the total adipose value, BAT and the Akkermansia
spp. and between Bacteroides spp. and the total adi-
pose tissue whilst a positive correlation was observed
between Lachnoclostridium counts and BAT. In Lab4-
TSHR, atrophy correlated negatively with Lachnoclos-
tridium spp. and uncultured Firmicutes as well as un-
cultured Bacteroidetes, whilst Akkermansia spp.
correlated negatively with the total adipose tissue
(Figure S6).
Modification of the gut microbiome affects disease
features to varying degree
To compare the effects of the various microbiota modifi-
cation treatments on characteristic disease features, the
percentages of mice positive for TSAbs, elevated T4, hy-
perplastic thyroid morphology, BAT and muscle atrophy
of each TSHR-immunized mouse group were evaluated
based on the upper 99% CI of the respective βgal mouse
group (Table S3). Percentages of positive TSHR-ddH2O
mice were set to 100% and the relative changes of posi-
tivity in the treated groups were calculated (Fig. 5a).
Fig. 5 Impact on autoimmune hyperthyroidism and orbitopathy and total disease outcomes of gut microbiota modifications. a Percentages of
positive untreated TSHR-immunized mice set to 100% and the changes of positivity in the treated groups Lab4, hFMT or vancomycin were
calculated. Changes in positive mice are given in % relative to untreated TSHR-immunized mice. Parameters were normalized using the Z-Score
(see the “Materials and methods” section). b Z-Score of autoimmune hyperthyroidism includes values of TSAbs and T4. c Z-Score of orbitopathy
evaluated by BAT and atrophic fibers. Data are presented as mean ± standard error of the mean. Statistical analysis was performed by two-way-
ANOVA; multiplicity adjusted P values are given as follows: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001. d, e Disease classification was based
on Z-score values. The number of mice is given in %, see STAR methods for classification parameters. Additionally, the number of mice in each
category is shown in Table S2
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Lab4 and hFMT, both increased the percentage of mice
positive for TSAb, elevated total serum T4 and orbital
BAT enlargement, but reduced mice with orbital muscle
atrophy. hFMT also strongly increased percentages of
mice with hyperplastic thyroid morphology. Vancomycin
reduced the percentage of mice positive for TSAb, ele-
vated T4, hyperplastic morphology and orbital BAT
whilst orbital atrophy was only mildly affected (Table S2
and Fig. 5a).
Modification of gut microbiome determines the total
outcome of disease
The differently treated TSHR-immunized mouse groups
developed autoimmune hyperthyroidism or orbitopathy
to varying degrees. To compare total disease outcome
between the mouse groups, we normalized and com-
bined the different parameters for each mouse by the Z-
score method as described earlier [27, 35, 42]. As shown
in Fig. 6, the TSHR-ddH2O mouse group (Z-score > 0)
can be clearly separated from βgal mouse group (Z-score
0) concerning autoimmune hyperthyroidism (P ≤
0.0001) and orbitopathy (P ≤ 0.0001) (Fig. 5b, c). Thus,
TSHR-ddH2O mice manifested significant overt disease
(termed clinical disease). Z-score values between 0 and 1
were defined as mild disease and Z-scores > 1 were
regarded as moderate-to-severe disease as described pre-
viously [42]. TSHR-immunized mice with Z-score < 0
were classified as normal-to-subclinical disease, i.e. have
only developed TSHR antibodies (Fig. 5b). Numbers of
mice showing normal-to-subclinical, clinical, mild or
moderate-to-severe disease are given in Table S3. Over-
all, hFMT and Lab4 increased the incidence and severity
of autoimmune hyperthyroidism whereas vancomycin
treatment led to mild or no disease compared with
TSHR-ddH2O (Fig. 5d). Regarding orbitopathy, 85% of
TSHR-ddH2O, 72% of Lab4 and 67% of hFMT mice de-
veloped either mild or moderate-to-severe disease. In
contrast, only 43% of vancomycin-treated TSHR-
immunized developed mostly mild GO (Fig. 5e).
Microbiome modification changes profile of lymphocytes
Flow cytometry analysis of orbital draining lymph node
revealed that CD4+ lymphocyte numbers remained un-
affected (Fig. 6a), whilst CD4+CD25+ (regulatory T cells;
Tregs) numbers were significantly lowered in vancomycin-
treated TSHR- and βgal-immunized mice (Fig. 6b) suggest-
ing lower autoimmunity incidence and disease severity that
we observed in this group is not necessarily regulated by
local mechanisms. Lab4-treated βgal mice showed sig-
nificantly higher Tregs compared with the ddH2O and
hFMT-βgal groups. However, such an elevation in
Tregs was not observed in Lab4-treated mice when they
underwent induction of GD/GO by receiving TSHR
immunization. TSHR-ddH2O mice showed positive
correlations between CD4+CD25+ levels and Bacter-
oides and Alistipes genera and between
Fig. 6 Effects of gut microbiome modification on lymph node T cell subsets, cytokine and chemokine levels. a CD4+ and b CD25+ T cell
population from draining lymph nodes of TSHR- and βgal-immunized mice in each treatment group. Data are presented as mean ± standard
error of the mean. Multiplicity adjusted P values are marked as ****P < 0.0001, *P < 0.05 (two-way ANOVA). c CCL5 and d IL-4 circulating
chemokines/cytokines from sera. Cytokine values are log10 transformed. Multiplicity adjusted P values are marked as *P < 0.05 (two-way ANOVA).
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Lachnospiraceae family. CD4+ levels negatively corre-
lated with six genera, including Bacteroides and Para-
bacteroides spp. In the vancomycin-TSHR
immunization group, Akkermansia spp. positively cor-
related with CD4+CD25+ levels, whilst an uncultured
Bacteroidetes was positively correlated with CD4+ T
cells. In Lab4-TSHR, genus Akkermansia negatively
correlated, whilst Alistipes spp. positively correlated
with CD4+CD25+ levels. Uncultured Bacteroidetes cor-
related positively with CD4+CD25 and negatively with
CD4+. Uncultured Actinobacteria displayed a strong
negative correlation to CD4+, as for Bacteroides and
Parabacteroides spp. In hFMT-TSHR, genera Bacter-
oides and Alistipes negatively correlated to CD4+ (Fig-
ure S6).
Microbiome modification affects circulating cytokine and
chemokine levels
Chemokines and cytokines were measured in sera at sac-
rifice using a multiplex system. Several were below the
limit of detection (IL-17/17A, IL-2 and IFN-γ), and no
significant differences were seen in IL-10, CCL20, IL-6
or TNF-alpha. The chemokine CCL5/RANTES showed
a trend to increase in TSHR-immunized compared with
βgal only in ddH2O treated mice (P = 0.37) whilst IL-4
was significantly higher in TSHR-ddH2O-compared with
βgal (P = 0.0170) (Fig. 6c). Vancomycin treatment in-
creased IL-4 levels significantly in βgal mice compared
to ddH2O treatment (P = 0.0286) and in βgal-
immunized mice compared to hFMT-TSHR mice (P =
0.0228) which correlated with Verrucomicrobia and Fir-
micutes. In TSHR-Lab4 IL-4 increased compared to
hFMT (P = 0.0208) (Fig. 6d).
Significant positive correlations between CCL5 and
two unidentified and uncultured Firmicutes were ob-
served in TSHR-ddH2O mice. A positive correlation be-
tween IL-4 and Akkermansia spp., a negative correlation
with Lachnoclostridium spp. Lab4-TSHR and a positive
correlation between CCL5 and Parabacteroides spp.
were reported in TSHR-vancomycin mice (Figure S6).
Discussion
The current study extends our previous work in which
we demonstrated significant differences in microbiota
composition from inbred BALB/c mice, undergoing the
same immunization protocol, in specific pathogen-free
(SPF) units in different locations. The results were ob-
tained using a robust GD/GO mouse model and sup-
ported our hypothesis that the bacterial environment
may contribute to determining TSHR-induced responses
and hence influence the outcome and reproducibility of
induced GD and GO.
For the first time, we investigated whether the gut
microbiota is necessary for the induction of GD/GO, by
modifying its composition from early-life and prior to
the hTSHR immunization regimen. Modulation of the
gut microbiome has been reported to improve or exacer-
bate other autoimmune diseases. We obtained striking
results: antibiotic treatment had a profound impact on
the gut microbiome which was associated with signifi-
cantly reduced GD-like disease (pathogenic autoanti-
bodies, elevated thyroxine, hyperthyroid thyroid
morphology) and GO-like histopathology and cellular
changes (orbital adipogenesis and muscle atrophy). In
contrast, mice receiving hFMT from patients with severe
GO, initially shared similarity of their gut microbiota
composition with their donors, accompanied by in-
creased severity of GD-like disease. The fact that muscle
atrophy decreased but orbital BAT volume was in-
creased in hFMT recipients suggests different pathogen-
etic mechanisms for these features of GO. Mice
receiving probiotic treatment had significantly higher
numbers of CD25+ Tregs in orbital draining lymph
nodes.
Consistent with previous findings [43], the effects of
long-term vancomycin treatment were dramatic and in-
cluded depletion of the richness and diversity indices ac-
companied by reduction of Gram-positive bacteria
(mainly Firmicutes phylum) and an increase in Proteo-
bacteria species, including Salmonella spp., Pseudo-
monas spp. and E. coli. Vancomycin also fostered growth
of resistant and/or compensating species, e.g. the highest
counts of the genus Bacteroides, which correlated nega-
tively with total orbital fat and genus Akkermansia
which showed a significant negative correlation with
brown and total fat, CD4+ and CD8+ in the orbit (data
not shown) and a positive correlation with the CD25+
(Tregs) in TSHR-immune mice. Akkermansia mucini-
phila constitutes a single-species of the genus Akker-
mansia [44], which is involved in mucin degradation
[45]. The postnatal administration of vancomycin in
non-obese diabetic (NOD) mice reduced the incidence
of T1D along with the increased proportion of A. muci-
niphila [46], although other studies showed exacerbation
of T1D in murine models and human subjects in the
presence of antibiotics [47, 48].
At the start of immunization, some hFMT mice had a
GO-like environment in their gut. In particular, mice
showing the highest engraftment were housed in the
same cage, suggesting a possible cage effect. However,
we repeated the analysis removing the “highly-colonized”
mice and similar results were confirmed (Figure S4). At
the midpoint (after 6 weeks of washout), no similarity
between hFMT-receiving mice and GO donors was ob-
served, whilst at the end of the experiment, the large in-
testines of both ddH2O and hFMT mice shared the
same similarity with human samples. The algorithm
used OTUs at the family level, which may lack host
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specificity, since no similarity was observed between
mice and humans at lower taxonomies. The definition of
FMT success is primarily based on a positive clinical re-
sponse in the recipient. However, from a microbiological
perspective, FMT success can also be defined by a shift
in the gut microbiome profile of an individual towards
that of the donor. We argue that a successful engraft-
ment may be a two-step process; first requiring the
transplanted microbiome to engraft within the new host
and augment the local commensal community, after
which clinical response may be observed.
The washout period may have reduced the transferred
bacteria, and the lack of prior treatment, such as bowel
cleansing or antibiotic treatment of dams, despite pups
being gavaged from birth, may have allowed some trans-
mission of maternal gut microbiota, which can induce
colonization resistance [49]. Of note, freeze-dried FMT
proved to be a safe and efficient treatment of diarrheal
episodes in recurrent Clostridioides difficile infections,
often accompanied by an increased/restored microbiota
diversity and a successful engraftment [50–52]. In mice,
after bowel cleansing, the engraftment of a single FMT
gavage lasted up to 4 weeks, whilst repeated gavages (i.e.
twice a week for 4 weeks) negatively impacted the stabil-
ity of the gut microbiota [53]. Furthermore we used fecal
material from people with severe GO, our parallel stud-
ies in patients with GD and/or GO reveal that most sig-
nificant differences in gut microbiota appeared in mild
GO, compared with GD or healthy controls. Bacterial
abundance and diversity of patients with severe GO
more closely resembled that of healthy controls, possibly
due to the extensive treatments, including corticoste-
roids, experienced by this group.
Probiotic supplements are associated with health bene-
fits in humans, including immune-modulation of the
recipient [54], and this was demonstrated in our Lab4-
treated mice. Specifically, CD4+CD25+ Tregs were in-
duced in the βgal, but not in the TSHR-immune group,
although the latter showed interesting correlations, e.g.
Bacteroidetes-uncultured genera, Bacteroides and Alis-
tipes negatively correlated with CD4+ and simultan-
eously positively with CD4+CD25+ Tregs. This suggests
that although probiotic treatment increases local Tregs,
this is unable to prevent breakdown in tolerance follow-
ing TSHR immunization.
The significantly lower CD4+CD25+ Tregs numbers in
vancomycin-treated mice in our study are in line with
previous findings. Vancomycin selectively targets gram-
positive bacteria which produce the short-chain fatty
acid butyrate [55]. Butyrate promotes the differentiation
of Tregs from naive CD4+ T cells and is known for its
anti-inflammatory effects [56].
Beneficial effects conferred by probiotics are not al-
ways related to the effective colonization of the host
mucosa by probiotic species and also occur transiently
[57]. Therefore, it was not surprising that no increase of
Lactobacillus sp. was observed in Lab4-treated LGI
microbiota. However, Bifidobacterium sp. was not de-
tected at all from the gut microbiota of our BALB/c
mice (even before the removal of low abundant OTUs),
as previously reported [25, 27, 28], possibly due to envir-
onmental factors (e.g. animal housing) or because of a
poor colonizer setting.
Lab4-treated TSHR-immune mice showed significantly
higher T4 levels and orbital brown fat compared to βgal.
Varian and collaborators treated aging outbred mice
daily with Lactobacillus reuteri and reported increased
T4 levels, accompanied by weight loss and increased ac-
tivity compared to untreated. Authors also observed an
enlarged thyroid and induced activity dependent upon
CD4+CD25+ Tregs [58]. Administration of L. acidophilus
for 32 days increased TSH and T3 levels but not T4 in
weaning rats [59]. Whilst providing a “healthful aging”
in 1-year-old mice [58], it is possible that probiotics
worsen hyperthyroidism following TSHR immunization.
On the contrary, supplementation of Bifidobacterium
lactis and Lactobacillus rhamnosus mitigated disease
outcome in experimental autoimmune thyroiditis (simi-
lar to Hashimoto’s thyroiditis) [11]. In Hashimoto’s thy-
roiditis patients, administration of probiotics stabilized
hormonal fluctuations during therapy, although no sig-
nificant protective effects were observed in hyperthyroid
humans compared to healthy controls [60]. In other
autoimmune conditions, prevention of T1D onset was
observed in NOD mice receiving multiple strains of
Lactobacillus and Bifidobacterium spp. and of Strepto-
coccus salivarius subsp. thermophilus which was associ-
ated with increased production of anti-inflammatory IL-
10 [61]. Similarly, administration of probiotics reversed
the EAE model phenotype with an upregulation of Tregs
via IL-10 production [62].
The study also shows some limitations. As mentioned
above, hFMT was not accompanied by any pre-
treatment. Usage of freeze-dried material would have
probably been more effective if we obtained samples
from mild GO rather than sight-threatening disease, par-
ticularly since patients had gone through massive inter-
ventions before donating fecal samples. If and how each
of those treatment regimens has influenced patients’ gut
microbiota is not completely clear. Moreover, despite
administering a probiotic containing two bifidobacteria
species, we were unable to detect them in any of the
mice studied, for the reasons already mentioned.
The fact that TSHR-immunized mice gained weight
was a surprise and contrasts with GD patients who lose
weight during the active stage of disease, although most
gain weight when TRAb-positive and euthyroid [63].
However, other than in patients, female mice were
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shown to gain weight in hyperthyroidism induced by T4
treatment, most likely due to higher food intake [64].
Likewise, in a recent study, we showed that hyperthyroid
TSHR immune mice gain weight [42]. Consistently, in
the current study, we found that weight gain correlated
positively with T4 values or with TSAb in the TSHR im-
mune mice but not in the βgal-ddH2O mice (Figure S9).
Of note, hFMT mice showed the most significant weight
gain suggesting a strong hyperthyroid hormone state
during the experimental course. Indeed, hFMT mice
showed the strongest elevated hyperactive thyroid
morphology confirming this assumption. Induction of
hyperthyroidism was highly variable in the mice,
whether assessed by T4 measurement or thyroid morph-
ology. The heterogeneity of autoimmune thyroid dys-
function in the model reflects the situation in patients
[26, 35]. Most GO patients had developed hyperthyroid-
ism when GO is diagnosed but some GO patients devel-
oped GO although euthyroid or even hypothyroid [65].
Whether and to what extent the thyroid hormone level
directly impacts/modulates the outcome of GO in the
model is unclear and needs to be addressed in further
studies.
Our findings are relevant to human disease, as illus-
trated by the similar perturbations of the gut microbiota
(increased Firmicutes and decreased Bacteroidetes) we
have found in TSHR-immunized mice and GD/GO pa-
tients (ms in preparation). Furthermore, long-term
vancomycin treatment resulted in a reduced and resilient
microbiota, which included high counts of Bacteroides
spp. (the opposite of that found in murine and human
GD/GO) and Akkermansia spp. Such an antibiotic-
modified-gut microbiota reduced incidence and severity
of disease induced by subsequent TSHR immunization.
In contrast, hFMT exacerbated GD-like pathology, i.e.
the disease phenotype had been partially transferred, and
was associated with the lowest Bacteroidetes counts of
all four TSHR-immunized groups. Whether increased
Firmicutes or decreased Bacteroidetes has more effect
on pathogenesis is not clear; some disease states have
been associated with gain of function perturbation of the
gut microbiota, e.g. colorectal cancer and Parkinson’s
disease whereas others have been associated with loss of
function imbalance, e.g. inflammatory bowel disease. Of
note, in most chronic conditions, decreased microbiota
diversity is a common theme [66].
The lack of induced disease in the vancomycin-treated
TSHR-immune mice confirms that the gut microbiota is
necessary for GD/GO to be successfully induced, poten-
tially training the immune system at the early stage of
life. Ivanov and collaborators reported a decreased
Th17-produced proinflammatory cytokines milieu in the
small intestines of the EAE newborn pups treated with
vancomycin, which may have contributed in the
protection from the disease development [67]. A very re-
cent paper by Su et al. reported significantly reduced
SCFA-producing bacteria in GD patients. Furthermore,
propionic acid from Bacteroides spp increased Tregs
whilst reducing Th17 cells [68]. This ties in with studies
from Fang and colleagues who identified a significantly
higher proportion of IL-17A-producing T cells in GO
patients and which correlated with orbital fibrotic
change [69]. In our experiments, circulating IL-17/17A,
IL-2 and IFN-γ levels were below the limit of detection,
although cytokine measurements were possible only at
the end of the experiment. In a few TSHR-immunized
mice, elevated levels of IL-10, IL-6, CCL-20 and TNF-
alpha were observed (data not shown). However, we did
observe a trend towards increased CCL5/RANTES levels
in TSHR-immunized mice, a chemokine which is re-
leased by orbital fibroblasts leading to T cell migration
and inflammatory responses [70]. IL-4, a cytokine pro-
duced by Th2 cells which is increased in serum of pa-
tients with GD [71] and which has mitogen effects on
fibroblasts [72], was found to be increased in TSHR-
ddH2O mice and in βgal mice after treatment with Lab4
or vancomycin. We did not confirm the reported reduc-
tion of IL-4 by treatment with probiotics [73] although
our findings agree with Sun and colleagues who showed
upregulation of IL-4 gene expression after vancomycin
treatment. Alternatively, since the TSHR-induced model
does not employ conventional adjuvants, given its close
interplay with the immune system, the gut microbiota
can itself act as a natural adjuvant, promoting (or
not) the second immune stimulus needed for the acti-
vation of the autoimmune response, as reported by
Oh and co-workers [74].
We speculate that the Lab4 administration promoted
an anti-inflammatory response, increasing the Tregs in
the βgal-ddH2O mice, which was neutralized by the
TSHR immunization, despite gut microbiota-correlating
features. Also, the lack of induced disease in
vancomycin-treated mice was accompanied by the lack
of Tregs in both βgal and TSHR mice. Future studies in
which immune cells are transferred from probiotic-
treated mice to naive recipients, prior to TSHR
immunization, will facilitate identification of the T cell
subsets implicated in GD/GO.
Conclusions
In conclusion, our results strongly support a pivotal role
for the gut microbiota in TSHR-induced disease (Suppl.
Figure S10). Whilst changes to the gut microbiota have a
profound effect on quantifiable GD endocrine and im-
mune factors, the impact on GO cellular changes is
more nuanced. Future studies will address the transla-
tional potential of our work, including clinical trials of
appropriate antibiotics, which are warranted to improve
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outcomes for patients with GD/GO. Also, a placebo-
controlled randomized trial with probiotics has been
conducted in patients to investigate the potential pro-
tective effect on hormonal fluctuations on GD/GO dur-
ing anti-thyroid treatments.
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Additional file 1: Supplementary methods. Table S1. Characteristics
of patients with sight-threatening GO recruited at the University Hospital
Duisburg-Essen providing samples for hFMT production.
Additional file 2: Figure S1. Supplementary results for the endpoint
gut microbiota analysis. (A and B) Microbiota composition according to
different anatomical samples in TSHR and βgal-immunized mice (sam-
ples/source: colon = 48, entire = 30, small = 51 from final timepoint and
stool = 105 from baseline and mid-timepoint). (A) Alpha-diversity indices
of the source of the microbiota sampled, Wilcoxon-Mann BH corrected
test: ***P < 0.05. (B) NMDS of Bray-Curtis distances according to immuni-
zations and sources at the endpoint. PERMANOVA between entire-colon
samples P > 0.05. (C and D) Endpoint composition of the LGI microbiota
amongst treatments in βgal-immunized mice. (n βgal mice/treatment at
endpoint: control = 8, hFMT = 8, Lab4 = 10, vancomycin = 19). (C) Alpha
diversity amongst treatments, Wilcoxon-Mann BH corrected test:***P <
0.001. (D to G) RandomForest of a model excluding vancomycin samples
(n mice/treatment endpoint: control = 20, hFMT = 19, Lab4 = 20). (D)
Confusion matrix for treatments w/o vancomycin samples. Diagonal
boxes represent the number of samples correctly predicted. (E) Top-10
variables of treatment classification according to the Mean Decrease Gini,
including the microbiota source as an effect related to figure E. (F) Confu-
sion matrix for immunizations in a model w/o vancomycin samples. (n
mice/immunization endpoint: TSHR = 33 and βgal = 26). (G) Top-10 vari-
ables of immunizations classification according to the Mean Decrease
Gini, including the microbiota source and treatments as an effect related
to figure G. Wilcoxon-Mann test with BH correction: ***P < 0.005; **P <
0.01; *P < 0.05.
Additional file 3: Figure S2. Heatmap of the differentially abundant
genera amongst treatments in TSHR-immunized mice. Median abun-
dances were scaled according to row Z-score. Only genera with P < 0.5
are represented.
Additional file 4: Figure S3. Heatmap of the differentially abundant
genera amongst treatments in βgal mice. Median abundances were
scaled according to row Z-score. Only genera with P < 0.5 are
represented.
Additional file 5: Figure S4. Composition of the fecal microbiota in GO
patients donating the samples for the hFMT (n = 6) and healthy controls
from the same region (n = 12). (A) Chao1 alpha-diversity index. Wilcoxon-
Mann test, P = 0.80. (B) Firmicutes to Bacteroidetes ratio. Wilcoxon-Mann
test, P = 0.60. (C) Heatmap of the top-50 most abundant genera in GO
patients and healthy controls. Each column represents a sample. Relative
abundances were scaled according to the row Z-score. (D) Viable com-
position of the fecal microbiota and of the freeze-dried powder used for
hFMT evaluated through a standard microbiology cultivation approach.
Missing bar-charts refer to a microorganism below the detection limit.
(EPS 625 kb)
Additional file 6: Figure S5. Supplementary results for the time-series
analysis. (A) Chao1 alpha-diversity indices at baseline, Wilcoxon-Mann test
with BH correction: ***P < 0.001. (n mice/treatment at baseline: control =
20, hFMT = 19, Lab4 = 20, vancomycin = 19). (B) Heatmap of the differen-
tially abundant genera amongst treatments at baseline. Median abun-
dances were scaled according to the row Z-score. Only genera with P <
0.05 are represented. (C) Alpha-diversity indices between timepoints in
each treatment group (n mice per treatment/timepoint: control baseline
= 16, mid = 20; hFMT baseline = 15, mid = 24; Lab4 baseline = 14, mid =
22; vancomycin baseline = 20, mid = 28), irrespective of the
immunizations. Wilcoxon-Mann test with BH correction: ***P < 0.005; **P
< 0.01; *P < 0.05.
Additional file 7: Figure S6. Correlation analysis between bacterial
biomarkers and disease features. Pearson’s correlation coefficient (r) was
used to test the correlations between bacterial biomarkers associated to
both treatments and immunizations (from Fig. 1e and g) in (A) ddH2O,
(B) vancomycin, (C) Lab4 and (D) hFMT treatment group at the final
timepoint. Only TSHR immunization is shown. Only correlations with P <
0.05 are shown and the strength of the correlation is represented by the
change in color from blue (negative) to red (positive correlation). (EPS
262 kb)
Additional file 8: Figure S7. Mice eye signs and orbital tissues
abnormalities analysed histologically. (A) Mice eye signs indicating orbital
disease. Representative images of a ßgal mouse lacking pathological eye
signs and of a TSHR-immunized mouse with acute signs of inflammation
and/or proptosis. (B) UCP-1 (uncoupling protein -1) as a marker for brown
fat tissue (BAT). Elevated portions of small vacuoled BAT were present in
TSHR-immunized mice. Representative pictures of stainings are shown. (C,
D) CD3 as a marker for T cells. Some CD3+ T cells (indicated by arrows)
were detected in adipose tissues (C) and in muscle tissues (D) of βgal
and TSHR-immunized mice. Immunohistochemistry of orbital tissues was
carried out as described in detail before [40]
Additional file 9: Figure S8. Caging effects during the hFMT
engraftment did not impact the induced phenotype. (A) Non-metric di-
mensional scaling (NMDS) based on Bray-Curtis distances according to
cages, specifically for the hFMT-receiving mouse group in each of the
timepoints sampled. Baseline and mid-timepoint used fecal samples,
whilst the final timepoint was on LGI microbiota. (B) Firmicutes to Bacter-
oidetes ratio in each hFMT-cage and in each timepoint. Pairwise
Wilcoxon-Mann test: **P < 0.05; ****P < 0.001, ns P > 0.05. (C and D) Re-
analysis without the samples from cage 8, as considered to be “high-col-
onized mice”. (C) Bacteroides spp. relative abundances between immuni-
zations and in each timepoint. Wilcoxon-Mann test: ns P > 0.05, **P <
0.01. (D) Random Forest confusion matrix of the classification for treat-
ments (all immunizations together) using the endpoint LGI genus-level
microbiota, as in Fig. 1e but without samples from cage 8. Diagonal
boxes represent the number of samples correctly predicted. (n mice/
group endpoint: control = 20, hFMT = 15, Lab4 = 20, vancomycin = 19).
(E and F) Evaluation of the autoimmune hyperthyroidism (E) and the GO
(F) Z-score with specific regard to the cage 8 samples. No significant dif-
ferences were observed between other samples. (EPS 272 kb)
Additional file 10: Figure S9. Correlation between weight gain and
clinical features. Pearson’s correlation coefficient (r) was used to test the
correlations between weight and T4 (A) and TSAb (B). (EPS 11601 kb)
Additional file 11: Table S2. Number of positive mice for each disease
parameter. Numbers of TSHR-immunized mice positive for thyroid-
stimulating antibodies (TSAbs), increased circulating thyroxine (T4), hyper-
plastic thyroid morphology, orbital brown fat (BAT) enlargement or
muscle fiber atrophy are reported. The threshold for positivity was de-
fined as upper 99% CI of the corresponding βgal groups. Table S3. Clas-
sification of total outcome of autoimmune hyperthyroidism and
orbitopathy. Disease classification was done along the Z-Score values in
Figure 8. The number of mice is given in %. Subclinical disease (Z-Score
<0): these mice displayed no overt signs of autoimmune hyperthyroidism
or orbitopathy although they developed TSHR antibodies. Clinical disease
(Z-Score >0): These mice displayed clear signs of autoimmune hyperthy-
roidism and/or orbital pathology. Clinical disease is classified in mild and
moderate/severe in accordance with the Z Score values as indicated
(mild: Z Score 01; moderate/severe: Z-Score >1).
Additional file 12: Figure S10. Schematic model. Modulation of the
gut microbiota in a mouse model of Graves‘ orbitopathy has an impact
on induced disease. Female BALB/c mice were immunized with TSHR-A
subunit and their intestinal microbiota were depleted with antibiotics
(vancomycin) or skewed with probiotics (Lab4) and human fecal material
transfer (hFMT) from severely affected patients with known increased Fir-
micutes/Bacteroidetes ratio, in order to study the effects of the micro-
biome on induced Graves’ Disease (GD)/ Graves’ orbitopathy (GO).
Incidence and severity of GD (TSHR autoantibodies, thyroid histology,
Moshkelgosha et al. Microbiome            (2021) 9:45 Page 17 of 20
thyroxine level) and GO (orbital fat and muscle histology), lymphocyte
phenotype, cytokine profile and gut microbiota were analysed at sacrifice
(~22 weeks) . The results show that, whilst microbiome manipulation with
all treatments specifically alter microbiome composition, hFMT increased
severity of GD-like disease but treatment with Lab4 exacerbated induced
autoimmune hyperthyroidism and GO. Vancomycin led to a significant in-
crease of the genus Bacteroides and less pronounced GD- and GO-like
changes.
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